Oligodendrogliomas

Oligodendrogliomas are a relatively rare type of glioma, a brain tumor that arises from oligodendrocytes, the cells in the brain and spinal cord that produce myelin, the substance that surrounds and protects nerve cells. These tumors are part of a group of tumors called gliomas, which are categorized based on the specific type of glial cell from which they originate. Oligodendrogliomas can occur in both adults and children, but they are most commonly diagnosed in middle-aged adults.

Grading of Oligodendrogliomas

Oligodendrogliomas are graded according to the World Health Organization (WHO) classification system, which considers factors such as the tumor's growth rate, presence of necrosis (tissue death), mitotic activity (cell division rate), and the cellular anaplasia (degree of abnormality in cell appearance). This grading helps in determining the aggressiveness of the tumor and planning the treatment strategy. The grades are:

Grade II (Low-Grade): These tumors are relatively slow-growing and less aggressive. They are characterized by a more uniform appearance of cells and fewer mitotic figures. Grade II oligodendrogliomas can sometimes be managed with surgery alone, depending on the tumor's location and extent.
Grade III (Anaplastic Oligodendrogliomas): These are more aggressive and fast-growing tumors with a higher rate of mitosis and cellular anaplasia. Anaplastic oligodendrogliomas are more likely to recur after treatment and require a more aggressive treatment approach, usually combining surgery, radiation therapy, and chemotherapy.

Survival Rates

The survival rates for oligodendroglioma patients vary significantly based on several factors, including the tumor's grade, the patient's age and overall health, the extent of surgical removal, and the tumor's genetic makeup. In general:

Grade II Oligodendrogliomas: Patients with these tumors have a relatively favorable prognosis, with 5-year survival rates ranging from 70% to 90%. The 10-year survival rate decreases but remains significant, highlighting the importance of long-term monitoring and management.
Grade III Anaplastic Oligodendrogliomas: These tumors have a less favorable prognosis, with 5-year survival rates ranging from 50% to 65%. The survival rates drop further for 10-year survival, reflecting the aggressive nature of these tumors.

Genetic Markers and Treatment Response

The prognosis and treatment response of oligodendrogliomas are also influenced by the presence of specific genetic alterations, particularly the co-deletion of chromosome arms 1p and 19q. Tumors with this genetic signature tend to respond better to chemotherapy and radiation and have a better overall prognosis compared to those without these alterations. Testing for 1p/19q co-deletion is now a standard part of the diagnostic process for oligodendrogliomas.

Treatment Options

The treatment plan for oligodendrogliomas typically involves a combination of therapies, tailored to the individual patient based on the tumor's characteristics and location, as well as the patient's overall health:

Surgical Resection: The initial treatment for oligodendrogliomas is often surgical removal of the tumor. The goal is to remove as much of the tumor as possible while minimizing damage to healthy brain tissue.
Radiation Therapy: This is commonly used after surgery, especially for anaplastic oligodendrogliomas, to kill any remaining tumor cells.
Chemotherapy: Drugs like PCV (procarbazine, lomustine, and vincristine) or temozolomide may be used, particularly for tumors with 1p/19q co-deletion, which tend to respond well to chemotherapy.

Research and Future Directions

Ongoing research is focused on better understanding the molecular and genetic bases of oligodendrogliomas to develop targeted therapies. Clinical trials are continually testing new drugs, drug combinations, and treatment approaches to improve outcomes for patients with these tumors.

It's important for patients with oligodendrogliomas to be treated at specialized centers where a multidisciplinary team can provide comprehensive care tailored to their specific situation. Advances in genetic testing, surgical techniques, and targeted therapies are gradually improving the prognosis for patients with oligodendrogliomas, offering hope for better outcomes in the future.

DONATE NOW and help us advance research to END brain cancer!